Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma

Vaccine

Volumn 31, Issue 23, 2013, Pages 2628-2637

  Tourdot, Sophie ^a   Airouche, Sabi ^a   Berjont, Nathalie ^a   Moussu, Hélène ^a   Betbeder, Didier ^b   Nony, Emmanuel ^a   Bordas Le Floch, Véronique ^a   Baron Bodo, Véronique ^a   Mascarell, Laurent ^a   Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

^b UFR3S Pharmacie   (France)

Author keywords

Allergy vaccine; Bet v 1; Birch pollen; Sublingual immunotherapy; Vector system

Indexed keywords

IMMUNOGLOBULIN A; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1A; UNCLASSIFIED DRUG;

AEROSOL; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BIRCH; BODY PLETHYSMOGRAPHY; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; LOEFFLER PNEUMONIA; LUNG LAVAGE; MOUSE; NONHUMAN; PNEUMONIA; POLLEN ALLERGY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TH2 CELL;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ANTIGENS, PLANT; ASTHMA; BETULA; BRONCHIAL HYPERREACTIVITY; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; PNEUMONIA; POLLEN; RANDOM ALLOCATION; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; TH2 CELLS; VACCINES;

EID: 84878345536     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.041     Document Type: Article

References (38)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 2:1572-1573.
2. Didier A., Melac M., Combebias A., Andre C. Efficacy and safety of sublingual immunotherapy grass pollen tablets in grass pollen rhinoconjonctivitis. J Allergy Clin Immunol 2006, 117:721.
3. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118:434-440.
4. Ibanez M.D., Kaiser F., Knecht R., Armentia A., Schopfer H., Tholstrup B., et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007, 18:516-522.
5. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121:512-518.
6. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., de Beaumont O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009, 123:160-166.
7. Didier A., Melac M., Montagut A., Lheritier-Barrand M., Tabar A., Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009, 64:166-171.
8. Horak F., Jaeger S., Worm M., Melac M., Didier A. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy 2009, 39:394-400.
9. Malling H.J., Montagut A., Melac M., Patriarca G., Panzner P., Seberova E., et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009, 39:387-393.
10. Canonica G., Bousquet J., Casale T., Lockey R., Baena-Cagnani C., Pawankar R., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64:1-59.
11. Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476.
12. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2:446-453.
13. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006, 61:15-19.
14. Batard T., Didierlaurent A., Chabre H., Mothes N., Bussieres L., Bohle B., et al. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol 2005, 136:239-249.
15. Himly M., Nony E., Chabre H., Van Overtvelt L., Neubauer A., van Ree R., et al. Standardization of allergen products: 1, detailed characterization of GMP-produced recombinant Bet v 1. 0101 as biological reference preparation. Allergy 2009, 64:1038-1045.
16. Pauli G., Larsen T.H., Rak S., Horak F., Pastorello E., Valenta R., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
17. Larenas-Linnemann D. Oralair Birch a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr Opin Investig Drugs 2010, 11:586-596.
18. Moingeon P., Lombardi V., Saint-Lu N., Tourdot S., Bodo V., Mascarell L. Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am 2011, 31:407-419.
19. Razafindratsita A., Saint-Lu N., Mascarell L., Berjont N., Bardon T., Betbeder D., et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007, 120:278-285.
20. Saint-Lu N., Tourdot S., Razafindratsita A., Mascarell L., Berjont N., Chabre H., et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009, 64:1003-1013.
21. Tourdot S., Airouche S., Berjont N., Da Silveira A., Mascarell L., Jacquet A., et al. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation. Clin Exp Allergy 2011, 41:1784-1792.
22. Swedin L., Ellis R., Kemi C., Ryrfeldt A., Inman M., Dahlen S.E., et al. Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness. Int Arch Allergy Immunol 2010, 153:249-258.
23. Allam J.P., Novak N., Fuchs C., Asen S., Berge S., Appel T., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:141-148.
24. Allam J.P., Peng W.M., Appel T., Wenghoefer M., Niederhagen B., Bieber T., et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008, 121:368-374.
25. Mascarell L., Lombardi V., Louise A., Saint-Lu N., Chabre H., Moussu H., et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008, 122:603-609.
26. Mascarell L., Saint-Lu N., Moussu H., Zimmer A., Louise A., Lone Y., et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal immunology 2011, 4:638-647.
27. Allam J.P., Novak N. Local immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol 2011, 11:571-578.
28. Reinhard C., Eder G., Fuchs H., Ziesenis A., Heyder J., Schulz H. Inbred strain variation in lung function. Mamm Genome 2002, 13:429-437.
29. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
30. Lloyd C.M. Building better mouse models of asthma. Curr Allergy Asthma Rep 2007, 7:231-236.
31. Holmes A.M., Solari R., Holgate S.T. Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 2011, 16:659-670.
32. Fernvik E., Peltre G., Senechal H., Vargaftig B.B. Effects of birch pollen and traffic particulate matter on Th2 cytokines, immunoglobulin E levels and bronchial hyper-responsiveness in mice. Clin Exp Allergy 2002, 32:602-611.
33. Wiedermann U., Jahn-Schmid B., Bohle B., Repa A., Renz H., Kraft D., et al. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. J Allergy Clin Immunol 1999, 103:1202-1210.
34. Wiedermann U., Herz U., Baier K., Vrtala S., Neuhaus-Steinmetz U., Bohle B., et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Immunol 2001, 126:68-77.
35. Wiedermann U., Herz U., Vrtala S., Neuhaus-Steinmetz U., Renz H., Ebner C., et al. Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma. Int Arch Allergy Immunol 2001, 124:391-394.
36. Winkler B., Baier K., Wagner S., Repa A., Eichler H.G., Scheiner O., et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002, 32:30-36.
37. Winkler B., Hufnagl K., Spittler A., Ploder M., Kallay E., Vrtala S., et al. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 2006, 61:173-180.
38. Liu Z., Guo H., Wu Y., Yu H., Yang H., Li J. Local nasal immunotherapy: efficacy of dermatophagoides farinae-chitosan vaccine in murine asthma. Int Arch Allergy Immunol 2009, 150:221-228.